0
0
Home » Medical Devices » Cardiovascular Devices

United States Cardiac Rhythm Management Devices Market Outlook to 2025 – Cardiac Resynchronisation Therapy (CRT), Implantable Cardioverter Defibrillators (ICD), Pacemakers and Implantable Loop Recorders (ILR)

GlobalData’s “United States Cardiac Rhythm Management Devices Market Outlook to 2025” is a comprehensive databook report, covering key market data on the United States Cardiac Rhythm Management Devices market. The databook report provides value (USD), volume (units) and average prices (USD) within market segments – Cardiac Resynchronisation Therapy (CRT), Implantable Cardioverter Defibrillators (ICD), Implantable Loop Recorders (ILR) and Pacemakers.

The United States Cardiac Rhythm Management Devices Market report provides key information and data on:

• Annualized market revenues (USD), volume (units) and average prices (USD) data for each of the market segments. Data is provided from 2015 to 2025.

• 2019 company share and distribution share data for Cardiac Rhythm Management Devices Market.

• Global corporate-level profiles of key companies operating within the United States Cardiac Rhythm Management Devices Market. Based on the availability of data for the particular category and country, information related to pipeline products, news and deals is also available in the report.

Scope

United States Cardiac Rhythm Management Devices is segmented as follows:

• Cardiac Resynchronisation Therapy (CRT)

• Implantable Cardioverter Defibrillators (ICD)

• Implantable Loop Recorders (ILR)

• Pacemakers

Reasons to Buy

Key Reasons to Purchase – The United States Cardiac Rhythm Management Devices Market report helps you to develop:

• Business strategies by identifying the key market segments poised for strong growth in the future.

• Market-entry and market expansion strategies.

• Design competition strategies by identifying who-stands-where in the market.

• Develop investment strategies by identifying the key market segments expected to register strong growth in the near future.

• Understand the key distribution channels and what’s the most preferred mode of product distribution – Identify, understand and capitalize.

Key Players

Key companies covered in the “United States Cardiac Rhythm Management Devices Market Outlook to 2025” report:

• Medtronic Plc

• Abbott Laboratories

• Biotronik AG

Table of Contents

1 Table of Contents

1 Table of Contents 2

1.1 List of Tables 5

1.2 List of Figures 5

2 Introduction 7

2.1 What Is This Report About? 7

2.2 Cardiac Rhythm Management Devices Market Segmentation 7

2.3 Definitions of Markets Covered in the Report 8

3 Cardiac Rhythm Management Devices Market, United States 10

3.1 Cardiac Rhythm Management Devices Market, United States, Revenue ($m), 2015-2025 10

3.1.1 Cardiac Resynchronisation Therapy (CRT) Market, United States, Revenue ($m), by Segment, 2015-2025 13

3.1.2 Implantable Cardioverter Defibrillators (ICD) Market, United States, Revenue ($m), by Segment, 2015-2025 15

3.1.3 Pacemakers Market, United States, Revenue ($m), by Segment, 2015-2025 17

3.2 Cardiac Rhythm Management Devices Market, United States, Volume (Units), 2015-2025 19

3.2.1 Cardiac Resynchronisation Therapy (CRT) Market, United States, Volume (Units), by Segment, 2015-2025 22

3.2.2 Implantable Cardioverter Defibrillators (ICD) Market, United States, Volume (Units), by Segment, 2015-2025 24

3.2.3 Pacemakers Market, United States, Volume (Units), by Segment, 2015-2025 26

3.3 Cardiac Rhythm Management Devices Market, United States, Average Price ($) , 2015-2025 28

3.4 Cardiac Rhythm Management Devices Market, United States, Distribution Share by Revenue ($m), 2019 30

3.5 Cardiac Rhythm Management Devices Market, United States, Company Share by Revenue ($m), 2019 31

4 Overview of Key Companies in United States, Cardiac Rhythm Management Devices Market 33

4.1 Medtronic Plc 33

4.1.1 Company Overview 33

4.2 Abbott Laboratories 33

4.2.1 Company Overview 33

4.3 Biotronik AG 33

4.3.1 Company Overview 33

4.4 Boston Scientific Corp 33

4.4.1 Company Overview 33

5 Cardiac Rhythm Management Devices Market Pipeline Products 34

6 Financial Deals Landscape 35

6.1 Debt Offerings 35

6.1.1 LivaNova USA Prices Private Placement of

3.00% Notes Due 2025 for USD250 Million 35

6.1.2 Boston Scientific Raises USD1.2 Billion in Public Offering of

2.65% Senior Notes due 2030 37

6.1.3 Boston Scientific Raises USD500 Million in Public Offering of

1.9% Senior Notes due 2025 39

6.1.4 Boston Scientific Raises USD999.2 Million in Public Offering of

0.625% Notes Due 2027 41

6.2 Equity Offerings 43

6.2.1 SurModics Plans to Raise up to USD200 Millon in Public Offering of Securities 43

6.2.2 Boston Scientific Raises USD1 Billion in Public Offering of Shares 44

6.2.3 Boston Scientific Raises USD1 Billion in Public Offering of

5.5% Mandatory Convertible Preferred Stock 46

6.2.4 Stereotaxis Files Registration Statement for Public Offering of Securities for up to USD100 Million 49

6.2.5 iRhythm Technologies Raises USD115 Million in Public Offering of Shares 50

6.2.6 Stereotaxis Raises USD25 Million in Private Placement of Common Stock 52

6.3 Private Equity 54

6.3.1 Stereotaxis to Raise USD15 Million in Private Placement of Shares 54

6.4 Venture Financing 55

6.4.1 EBR Systems Raises USD30 Million in Venture Financing 55

7 Recent Developments 57

7.1 Corporate Communications 57

7.1.1 Mar 03, 2020: Ocular Therapeutix Provides update on interim data from the OTX-TKI Phase 1 clinical trial at the Cowen 40th Annual Health Care Conference 57

7.1.2 Feb 03, 2020: Surmodics names Nusrath Sultana, MD, as Vice President, Clinical Affairs 58

7.1.3 Dec 10, 2019: New Menarini CELLSEARCH studies to be presented at San Antonio Breast Cancer Symposium 58

7.1.4 Dec 05, 2019: Orthofix names Kevin Kenny president of global spine business 60

7.1.5 Nov 01, 2019: Orthofix appoints Jon Serbousek as President and Chief Executive Officer 60

7.1.6 Sep 24, 2019: Jaguar Health to host investor call to provide updates regarding development of Mytesi for the potential follow-on indication of cancer therapy-related diarrhea 61

7.1.7 Sep 16, 2019: Stereotaxis announces CFO transition 62

7.1.8 Aug 20, 2019: FDA accepts New Drug Application for VX-445 (Elexacaftor), Tezacaftor and Ivacaftor combination treatment 62

7.1.9 Aug 05, 2019: Orthofix names Jon Serbousek to Succeed CEO 62

7.1.10 Jul 24, 2019: Former Medtronic Executive Sean Ginney named VP of Sales at Current Health 63

7.2 Financial Announcements 64

7.2.1 Feb 05, 2020: Boston Scientific announces results for fourth quarter and full year 2019 64

7.2.2 Feb 05, 2020: Surmodics reports first quarter Fiscal 2020 results 65

7.2.3 Jan 28, 2020: Beckman Coulter's Access PCT Procalcitonin Assay receives U.S. FDA 510(k) clearance 66

7.2.4 Jan 14, 2020: Boston Scientific announces preliminary unaudited sales for the fourth quarter and full year 2019 66

7.2.5 Dec 23, 2019: iRhythm Technologies files quarterly report on form 10-Q for third quarter 2019 and updates guidance for full year 2019 67

7.2.6 Dec 09, 2019: ImaginAb initiates phase II clinical trial at Penn Medicine 68

7.2.7 Nov 14, 2019: Stereotaxis reports 2019 third quarter financial results 70

7.2.8 Nov 05, 2019: iRhythm Technologies announces third quarter 2019 financial results 70

7.2.9 Oct 31, 2019: Surmodics reports fourth quarter fiscal 2019 results and issues fiscal 2020 revenue and EPS Guidance 71

7.2.10 Oct 28, 2019: Orthofix reports third quarter 2019 results 72

7.2.11 Oct 23, 2019: Boston Scientific announces results for third quarter 2019 73

7.2.12 Sep 25, 2019: Katerzia, the first and only amlodipine oral suspension, 1 mg/mL, is now commercially available for pediatric patients 6 years of age and older 74

7.2.13 Sep 02, 2019: Quantum Genomics Announces Positive FDA Feedback on Phase III Program Design of Firibastat in Resistant Arterial Hypertension 75

7.2.14 Aug 08, 2019: Stereotaxis reports 2019 second quarter financial results 76

7.2.15 Aug 07, 2019: USRM posts earnings for second quarter 2019 77

7.2.16 Aug 05, 2019: Orthofix reports second quarter 2019 results 77

7.2.17 Jul 31, 2019: iRhythm Technologies Announces Second Quarter 2019 Financial Results 78

7.2.18 Jul 31, 2019: Surmodics reports third quarter fiscal 2019 results and raises fiscal 2019 revenue and EPS guidance 79

7.2.19 Jul 29, 2019: Lourdes Felix, Chief Operating Officer and Chief Financial Officer of BioCorRx discusses the launch of the UnCraveRx Virtual App in a new interview at SmallCapVoice.com 80

7.2.20 Jul 24, 2019: Boston Scientific announces results for second quarter 2019 80

7.3 Government and Public Interest 81

7.3.1 Sep 09, 2019: Theravance Biopharma reports positive results from phase 1 clinical trial of TD-8236, an investigational, lung-selective, inhaled Pan-Janus Kinase (JAK) inhibitor for inflammatory lung diseases 81

7.3.2 Sep 05, 2019: New caregiver-reported data further validate the use of the aberrant behavior checklist community: FXS specific (ABC-CFXS) subscales to assess core behavioral symptoms of Fragile X Syndrome (FXS) 84

7.3.3 Aug 29, 2019: Parker Waichman LLP and The Drakulich Firm File TDF Lawsuit 85

7.4 Other Significant Developments 87

7.4.1 Apr 14, 2020: BioCardia announces litigation financing in the case captioned Boston Scientific 87

7.4.2 Mar 04, 2020: CytoDyn treats first patient with Leronlimab in Phase 2 trial for GvHD under modified trial protocol 87

7.4.3 Aug 28, 2019: Boston Scientific Celebrates 15th Anniversary in Costa Rica 89

7.4.4 Jul 10, 2019: Medtronic announces the early results of its cash tender offers for up to $5.525 billion of certain outstanding debt securities 89

7.5 Product News 90

7.5.1 Nov 22, 2019: Stereotaxis CEO to present at the 12th Annual BIOMEDevice San Jose Conference 90

7.5.2 Jul 23, 2019: ZOLL rebrands Payor Logic Solutions as ZOLL AR Boost 91

7.6 Strategy And Business Planning 91

7.6.1 Jul 19, 2019: Midatech announces safety results from first in human study for injectable MidaCore Gold nano particle diabetes vaccine programme – MTX102 91

8 Appendix 93

8.1 Research Methodology 94

8.1.1 Coverage 94

8.1.2 Secondary Research 94

8.1.3 Primary Research 95

8.1.4 Market Modeling and Forecasting 96

8.1.5 Company Share Analysis 97

8.1.6 Distribution Share Analysis 98

8.1.7 Benchmarking 98

8.2 GlobalData Consulting 99

8.3 Contact Us 99

8.4 Disclaimer 99

List of Tables

1.1 List of Tables

Table 1: Cardiac Rhythm Management Devices Market, United States, Revenue ($m), USD Constant, 2015-2020 10

Table 2: Cardiac Rhythm Management Devices Market, United States, Revenue ($m), USD Constant, 2021-2025 11

Table 3: Cardiac Resynchronisation Therapy (CRT) Market, United States, Revenue ($m), USD Constant, 2015-2020 13

Table 4: Cardiac Resynchronisation Therapy (CRT) Market, United States, Revenue ($m), USD Constant, 2021-2025 13

Table 5: Implantable Cardioverter Defibrillators (ICD) Market, United States, Revenue ($m), USD Constant, 2015-2020 15

Table 6: Implantable Cardioverter Defibrillators (ICD) Market, United States, Revenue ($m), USD Constant, 2021-2025 15

Table 7: Pacemakers Market, United States, Revenue ($m), USD Constant, 2015-2020 17

Table 8: Pacemakers Market, United States, Revenue ($m), USD Constant, 2021-2025 17

Table 9: Cardiac Rhythm Management Devices Market, United States, Volume (Units), 2015-2020 19

Table 10: Cardiac Rhythm Management Devices Market, United States, Volume (Units), 2021-2025 20

Table 11: Cardiac Resynchronisation Therapy (CRT) Market, United States, Volume (Units), 2015-2020 22

Table 12: Cardiac Resynchronisation Therapy (CRT) Market, United States, Volume (Units), 2021-2025 22

Table 13: Implantable Cardioverter Defibrillators (ICD) Market, United States, Volume (Units), 2015-2020 24

Table 14: Implantable Cardioverter Defibrillators (ICD) Market, United States, Volume (Units), 2021-2025 24

Table 15: Pacemakers Market, United States, Volume (Units), 2015-2020 26

Table 16: Pacemakers Market, United States, Volume (Units), 2021-2025 26

Table 17: Cardiac Rhythm Management Devices Market, United States, Average Price ($), 2015-2020 27

Table 18: Cardiac Rhythm Management Devices Market, United States, Average Price ($), 2021-2025 28

Table 19: Cardiac Rhythm Management Devices Market, United States, Distribution Share by Revenue ($m), USD Constant, 2019 29

Table 20: Cardiac Rhythm Management Devices Market, United States, Company Share by Revenue ($m), USD Constant, 2019 31

Table 21: Cardiac Rhythm Management Devices Market Pipeline Products 33

Table 22: LivaNova USA Prices Private Placement of 3.00% Notes Due 2025 for USD250 Million 34

Table 23: Boston Scientific Raises USD1.2 Billion in Public Offering of 2.65% Senior Notes due 2030 36

Table 24: Boston Scientific Raises USD500 Million in Public Offering of 1.9% Senior Notes due 2025 38

Table 25: Boston Scientific Raises USD999.2 Million in Public Offering of 0.625% Notes Due 2027 40

Table 26: SurModics Plans to Raise up to USD200 Millon in Public Offering of Securities 42

Table 27: Boston Scientific Raises USD1 Billion in Public Offering of Shares 43

Table 28: Boston Scientific Raises USD1 Billion in Public Offering of 5.5% Mandatory Convertible Preferred Stock 45

Table 29: Stereotaxis Files Registration Statement for Public Offering of Securities for up to USD100 Million 48

Table 30: iRhythm Technologies Raises USD115 Million in Public Offering of Shares 49

Table 31: Stereotaxis Raises USD25 Million in Private Placement of Common Stock 51

Table 32: Stereotaxis to Raise USD15 Million in Private Placement of Shares 53

Table 33: EBR Systems Raises USD30 Million in Venture Financing 54

Table 34: Total Number of Primary Research Participants, Cardiovascular Devices Market, by Country 95

List of Figures

1.2 List of Figures

Figure 1: Cardiac Rhythm Management Devices Market, United States, Revenue ($m), USD Constant, 2015-2025 10

Figure 2: Cardiac Resynchronisation Therapy (CRT) Market, United States, Revenue ($m), USD Constant, 2015-2025 13

Figure 3: Implantable Cardioverter Defibrillators (ICD) Market, United States, Revenue ($m), USD Constant, 2015-2025 15

Figure 4: Pacemakers Market, United States, Revenue ($m), USD Constant, 2015-2025 17

Figure 5: Cardiac Rhythm Management Devices Market, United States, Volume (Units), 2015-2025 19

Figure 6: Cardiac Resynchronisation Therapy (CRT) Market, United States, Volume (Units), 2015-2025 22

Figure 7: Implantable Cardioverter Defibrillators (ICD) Market, United States, Volume (Units), 2015-2025 24

Figure 8: Pacemakers Market, United States, Volume (Units), 2015-2025 26

Figure 9: Cardiac Rhythm Management Devices Market, United States, Company Share (%) 2019 31

    Pricing

Discounts available for multiple purchases.

reportstore@globaldata.com
+44 20 7947 2960

Join our mailing list

Saved reports